Vancouver, BC Biotechnology and Pharmaceutical Companies Directory

Vancouver, BC Biotechnology and Pharmaceutical Companies directory and business contacts list

The following Vancouver, BC, Canada Biotechnology and Pharmaceutical Companies are among the many key British Columbia organizations listed in the BC Contacts Directory. Try BC Contacts today for free!

Dr. Terrance Snutch, co-Founder, Vice President & Chief Scientific Officer
Neuromed Pharmaceuticals Ltd.
301 - 2389 Health Sciences Mall
Vancouver, BC V6T 1Z4
Tel. 604 909-2530
Fax. 604 909-2538
TSnutchvs7@neuromedtech.com
infovs7@neuromedtech.com
www.neuromedtech.com

Kourosh Moaref, Manager
Symbiorph Biomedical Corporation
203 - 1099 West 8th Avenue
Vancouver, BC V6H 1C3
Tel. 604 637-5727
Fax. 604 608-4725
kourosh.moarefoe05q@symbiorph.com
infooe05q@symbiorph.com
www.symbiorph.com

Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you.

Try BC Contacts today for free!

Add or update company & contact information, or send feedback to directory maintainers.

Top of page

Ali Tehrani, Ph.D., Co-Founder, President and Chief Executive Officer
Zymeworks Inc.
540 - 1385 West 8th Avenue
Vancouver BC V6H 3V9
Tel. 604 678-1388
Fax. 604 737-7077
infoav@zymeworks.com
www.zymeworks.com

Dr. Tehrani is one of Zymeworks' co-founders and currently serves as President and CEO of the company. He has been an integral part of many of the Company's corporate achievements including raising seed and angel financing and overseeing the Company's technical operations and patent filings. Dr. Tehrani holds both Bachelors and Masters of Science degrees in Biochemistry from the University of Massachusetts, and has a Doctoral degree in Microbiology and Immunology from the University of British Columbia.

While completing his PhD degree he co-founded the Student Biotechnology Network, for which he received the UBC Faculty of Science Achievement Award for Outstanding Leadership in 2002. Dr. Tehrani also serves on the MITACS Industrial Advisory Board, and BIOTECanada's Industrial and Environmental Committee. He is also the Chair of the Life Sciences British Columbia Bioproducts and Bioenergy advisory committee.

Jodi Regts, Senior Manager, Investor Relations and Corporate Communications
Angiotech Pharmaceuticals Inc.
1618 Station Street
Vancouver, BC V6A 1B6
Tel. 604 221-7930 - direct
Tel. 604 221-7676
Fax. 604 221-2330
jregtsjzvgr16@angio.com
infojzvgr16@angio.com
www.angiotech.com

Arc Rajtar, Chief Technology Officer
MIV Therapeutics Inc.
1 - 8765 Ash Street
Vancouver, BC V6P 6T3
Tel. 604 301-9545 X 22 - direct
Tel. 604 301-9545
Fax. 604 301-9546
arajtaro8w0wrf@mivi.ca
contacto8w0wrf@mivtherapeutics.com
www.mivtherapeutics.com

Mr. Rajtar came to MIVT in February 2002 with a strong background in the development of medical devices. He has extensive experience in a broad range of advanced technologies and served previously in a number of executive positions with world-class companies.

Over the last 14 years he served in key positions with startup companies in the medical device field and other areas integral to the medical industry. Mr. Rajtar also serves as an adjunct professor at the University of British Columbia's Faculty of Metals and Materials Engineering.

Rajtar is also a Director of MIVI Technologies Inc., a wholly-owned manufacturing and research and development arm of MIVT, where his responsibilities include coordination of research and validation programs, and key support to business development initiatives toward the expected commercialization of MIVT's proprietary technologies.

Sally Greenwood, Director, Communications & Education
Genome British Columbia / Genome BC
500 - 555 West 8th Avenue
Vancouver BC V5Z 1C6
Tel. 604 637-4373 - direct
Tel. 604 738-8072
Fax. 604 738-8597
sgreenwoodaw@genomebc.ca
infoaw@genomebc.ca
www.genomebc.ca

Sally Greenwood brings over 18 years of experience in the non-profit, health care and social services sectors. Most recently she was the Director of Communications for Community Living BC (Crown Agency). She also held senior positions with BC Transplant and the BC Centre for Disease Control, agencies of the Provincial Health Services Authority.

Prior to her move to the field of transplantation and public health, Sally worked for the Multiple Sclerosis Society of Canada, BC Division as the Director for Development and Communications. Her communications experience spans government and stakeholder relations, marketing communications and educational and program development. Much of her focus over the last few years has been in the area of strategic change communications as she participated directly in major health care and social service reorganizations.

She attended the University of British Columbia where she completed an undergraduate degree in English before attending Ryerson Polytechnic University in Toronto to continue with graduate studies in journalism.

Aaron Keay, Manager, Investor Relations
Allon Therapeutics Inc.
506 - 1168 Hamilton Street
Vancouver, BC V6B 2S2
Tel. 604 742-2540 - direct
Tel. 604 736-0634
Fax. 604 736-1616
akeayg7y@allontherapeutics.com
infog7y@allontherapeutics.com
www.allontherapeutics.com

Top of page

Marianne Sadar, Senior Scientist/Program Leader, Prostate Cancer Research
Michael Smith Genome Sciences Centre / BC Cancer Research Centre
675 West 10th Avenue
Vancouver BC V5Z 1L3
Tel. 604 675-8150 X 8157 - direct
Tel. 604 675-8150
Fax. 604 675-8178
msadar5cn4b@bcgsc.ca
info5cn4b@bcgsc.bc.ca
www.bcgsc.ca

Amanda Smith, Corporate Communications (via Smith Biotech)
ARC Pharmaceuticals Inc.
102 - 2386 East Mall
Vancouver, BC V6T 1Z3
Tel. 778 846-4116 - cell
Tel. 604 222-9577
Fax. 604 222-9578
amanda3m@smithbiotech.com
info3m@arcpharma.com
www.arcpharma.com

Amanda Smith runs Smith Biotech (in this directory).

Martin Schweizer, PhD, Manager, Technical Development
Burcon NutraScience Corporation
1946 West Broadway
Vancouver, BC V6J 1Z2
Tel. 604 733-0896
Fax. 604 733-8821
MSchweizer6o@burcon.ca
info6o@burcon.ca
www.burcon.ca

Dr. Schweizer joined Burcon in May of 2002 as a process-engineering specialist. He relocated from Nancy, France, where he earned his doctorate at the Institut National Polytechnique de Lorraine, with an emphasis on the enzymatic hydrolysis of rapeseed proteins.

Prior to his Ph.D. work, Dr. Schweizer studied chemical engineering at the University of Karlsruhe, Germany, where he specialized in food process engineering and water technology. Since January of 2003, Dr. Schweizer has overseen Burcon's research and development efforts at its Winnipeg Technical Center.

Sandra Haney, Director of Communications and Marketing
PrioNet Canada
200 - 2386 East Mall
Vancouver, BC V6T 1Z3
Tel. 604 222-3611 - direct
Tel. 604 222-3600
Fax. 604 222-3606
shaneyjt@prionetcanada.ca
adminjt@prionetcanada.ca
www.prionetcanada.ca

Sandra has held various communications and marketing roles related to research and technology transfer over the last ten years. She was recently at UBC's University-Industry Liaison Office, one of the most successful offices of its kind in North America.
Prior to this, she spent four years at WestLink Innovation Network, playing an integral role in launching its successful technology commercialization internship program.

Sandra has freelanced in media relations, public relations, event management, and web site development for a range of organizations. She graduated from the University of Alberta in 1998 with a Bachelor of Science in Environmental and Conservation Sciences.

Sandra manages all of the internal and external communications of PrioNet Canada such as its newsletter, web site, reports, media, and marketing items. She also oversees various events and knowledge exchange programs.

Jennifer Siegfried, Marketing Specialist
LifeSciences British Columbia / LifeSciences BC
900 - 1188 West Georgia Street
Vancouver, BC V6E 4A2
Tel. 604 602-5227 - direct
Tel. 604 669-9909
Fax. 604 669-9912
jsiegfriedct2dk@lifesciencesbc.ca
www.lifesciencesbc.ca

Top of page

Dorothy Law, BComm, LLB, Director, Vice President, Legal and Corporate Secretary
Burcon NutraScience Corporation
1946 West Broadway
Vancouver, BC V6J 1Z2
Tel. 604 733-0896
Fax. 604 733-8821
DLawrr@burcon.ca
inforr@burcon.ca
www.burcon.ca

Ms. Law joined the Burcon group of companies in August 1997. Prior to this, she was an associate lawyer at the national law firm of Lang Michener Lawrence & Shaw, practicing primarily in the areas of securities and corporate law.

She has served on the board of other public companies and currently is a director of China Enterprises Limited, whose shares are quoted on the OTC Bulletin Board.

Ms. Law was admitted as a member of the Law Society of British Columbia in August 1996. She was also admitted as a solicitor in the High Court of Hong Kong in May 1999. Ms. Law holds bachelor of laws and bachelor of commerce degrees from the University of British Columbia.

Jennifer Sangster,
Forbes Medi-Tech Inc.
200 - 750 West Pender Street
Vancouver, BC V6C 2T8
Tel. 604 689-5899 X 248 - direct
Tel. 604 689-5899
Fax. 604 689-7641
JSangsterxnb844@forbesmedi.com
infoxnb844@forbesmedi.com
www.forbesmedi.com

Steve Danic, Director, Information Systems
Angiotech Pharmaceuticals Inc.
1618 Station Street
Vancouver, BC V6A 1B6
Tel. 604 221-7676
Fax. 604 221-2330
SDanicto3d2l2t@angio.com
www.angiotech.com

Nina Merchant, M.E.Sc. Vice President, Development and Regulatory Affairs
Protox Therapeutics Inc.
1210 - 885 West Georgia Street
Vancouver, BC V6C 3E8
Tel. 604 688-0199
Fax. 604 688-0173
NMerchantr1265i1zj@protoxtherapeutics.com
infor1265i1zj@protoxtherapeutics.com
www.protoxtherapeutics.com

Andrew Rae, MBA, President, Chief Executive Officer and Director
iCo Therapeutics Inc.
760 - 777 Hornby Street
Vancouver, BC V6Z 1S4
Tel. 604 602-9414
Fax. 604 602-9699
raeehx@icotherapeutics.com
infoehx@icotherapeutics.com
www.icotherapeutics.com

Mr. Rae is currently President and CEO of iCo Therapeutics, Inc., an ocular development company he co-founded in 2005. Andrew has spent a decade in the biotechnology industry, formerly as CFO with Ability Biomedical Corporation (Irvine CA, Vancouver BC), acquired by Medarex, Inc. in 2004.

Mr. Rae has also served as Vice President, Finance & Corporate Affairs at Active Pass Pharmaceuticals (Vancouver BC). Mr. Rae has raised approximately $25M in venture financing, engaged in a successful cross-border M&A transaction, and played a significant role in shaping multiple business development deals (Cambridge Antibody, Isis Pharmaceuticals, Medarex).

Prior to his operational experiences, Mr. Rae served as Biotechnology Equities Analyst, Goepel Shields & Partners (now Raymond James Canada), covering Canadian biotechnology stocks including Angiotech Pharmaceuticals, QLT Inc. and ID Biomedical.

Mr. Rae currently sits on the Board of Directors of Migenix, a biotechnology company in Vancouver BC, the Dean's External Advisory Board for the Faculty of Business Administration at Simon Fraser University, and the Board of Directors of Covenant House Vancouver, a charity operating shelters and counsel to homeless youth in Vancouver, BC.

He previously served on the Board of Directors (including Audit, Nomination and Governance Committees) for Liponex Inc., a Canadian, TSE-listed biopharmaceutical research company. Mr. Rae's degrees include a B.Sc. from the University of Western Ontario and an MBA from Simon Fraser University.

Top of page

Gordon McCauley, President and Chief Executive Officer
Allon Therapeutics Inc.
506 - 1168 Hamilton Street
Vancouver, BC V6B 2S2
Tel. 604 742-2540 - direct
Tel. 604 736-0634
Fax. 604 736-1616
gmccauleyxh9uy3c@allontherapeutics.com
infoxh9uy3c@allontherapeutics.com
www.allontherapeutics.com

Michael Roberts, Vice President, Human Resources
Angiotech Pharmaceuticals Inc.
1618 Station Street
Vancouver, BC V6A 1B6
Tel. 604 221-7676
Fax. 604 221-2330
MRobertsbtvnc@angio.com
infobtvnc@angio.com
www.angiotech.com

Roberts is a Human Resource executive with extensive experience in compensation, recruitment, employment law, performance management, and the development and implementation of HR policies and practices. Michael joined Angiotech Pharmaceuticals in March 2004 as Vice President, Human Resources.

Following graduate school, Michael worked for Nortel Networks in a number of HR management roles, most recently Senior Manager, Executive Compensation Policies & Programs. Michael then joined Ballard Power Systems, Inc. in 1995.

As Director, Human Resources, Michael developed and implemented Ballard's key HR policies and programs, including innovative compensation, recruitment, and recognition programs. During his tenure, Ballard grew from 175 employees to over 1,000 employees. From 2002 to 2003, Michael was Vice President, Human Resources for NxtPhase Corporation.

Michael holds a B.A. (Hons.) from the University of Calgary and an M.B.A. from the University of British Columbia.

Ruth Appanah, Laboratory Coordinator
Michael Smith Genome Sciences Centre / BC Cancer Research Centre
675 West 10th Avenue
Vancouver BC V5Z 1L3
Tel. 604 675-8000 X 7982 - direct
Tel. 604 675-8150
Fax. 604 675-8178
rappanaha@bcgsc.ca
infoa@bcgsc.bc.ca
www.bcgsc.ca

W. Douglas Grant, Chief Financial Officer
Vitality Products Inc.
304 - 837 West Hastings Street
Vancouver, BC V6C 3N6
Tel. 604 683-6611
Fax. 604 662-8524
wngrant7wc0704@telus.net
info7wc0704@vitality.ca
www.vitality.ca

Becky Gillespie, Project Coordinator
Michael Smith Genome Sciences Centre / BC Cancer Research Centre
675 West 10th Avenue
Vancouver BC V5Z 1L3
Tel. 604 707-5900 X 5413 - direct
Tel. 604 675-8150
Fax. 604 675-8178
bgillespie3t7g10@bcgsc.ca
info3t7g10@bcgsc.bc.ca
www.bcgsc.ca

Top of page

David Kwok, Ph.D., President & Chief Executive Officer
BRI Biopharmaceutical Research Inc.
101 - 8898 Heather Street
Vancouver, BC V6P 3S8
Tel. 604 432-9237
Fax. 604 432-9239
DKwokhd5sz@bripharm.com
infohd5sz@bripharm.com
www.bripharm.com

Dr. David Kwok is the founder and current President and CEO of BRI. Dr. Kwok is a key scientific and technical member at BRI, providing the company with a broad scope of drug development experience and practical expertise on many challenging technical issues encountered during preclinical development.
Dr. Kwok graduated with a Pharmacy Bachelor's degree from the University of British Columbia, followed by his M.Sc. and Ph.D. in medicinal analytical chemistry in 1991. He served in a variety of management and scientific positions at Health Canada from 1991 to 1998, responsible for botanical safety and quality control, anti-microbial drug resistance and veterinary drug safety laboratory programs.

He has been an invited speaker at numerous professional conferences and has contributed to over 30 scientific publications in bioanalytical chemistry applications and drug candidate optimization studies in peer-reviewed journals, poster presentations, and scientific review journals.

Victor Luk, Facilities Manager
Michael Smith Laboratories
The University of British Columbia
301 - 2185 East Mall
Vancouver BC V6T 1Z4
Tel. 604 822-2264 - direct
Tel. 604 822-4838
Fax. 604 822-2114
vluk5gr@msl.ubc.ca
www.michaelsmith.ubc.ca

Dr. Andrew Janoff, Ph.D., Chief Executive Officer and Chairman
Celator Pharmaceuticals Corp.
1779 West 75th Avenue
Vancouver, BC V6P 6P2
Tel. 604 708-5858
Fax. 604 708-5883
AJanoff60@celatorpharma.com
info60@celatorpharma.com
www.celatorpharma.com

Scott Cormack, Founder, President and Chief Executive Officer
OncoGenex Pharmaceuticals / OncoGenex Technologies Inc.
400 - 1001 West Broadway
Vancouver, BC V6H 4B1
Tel. 604 805-2274 - direct
Tel. 604 736-3678
Fax. 604 736-3687
scormackvylr9@oncogenex.ca
mediavylr9@oncogenex.ca
www.oncogenex.ca
www.oncogenex.com

Cormack is the founding President and CEO of OncoGenex. He has almost two decades of diverse experience in the biotechnology industry in executive management, research and development, regulatory affairs, business development, operations, sales and marketing and corporate finance.

At Vetrepharm Research (now Bioniche Life Sciences), Mr. Cormack successfully led the development of the company's immunotherapeutic from lab bench through preclinical development and into clinical trials in oncology.

This technology was also successfully applied to vaccines as an adjuvant, and as an immunotherapy for viral diseases and oncology in veterinary indications and was approved for marketing in multiple countries. Mr. Cormack subsequently expanded his business development and operational skills, initially as Business Development and then as Chief Operating Officer of NeuroSpheres, Inc.

Immediately prior to joining OncoGenex, Mr. Cormack served as the Vice President, Western Region for Milestone Medica Corporation, where he was responsible for managing the western operations of this seed-capital investment fund.

Under his tenure, Milestone Medica co-founded and funded start-up companies in Western Canada, including OncoGenex. Mr. Cormack acted as interim President and CEO of OncoGenex from inception until his appointment as full-time President and CEO in January, 2002.

John Parkinson, Chief Financial Officer
Protox Therapeutics Inc.
1210 - 885 West Georgia Street
Vancouver BC V6C 3E8
Tel. 604 688-0199
Fax. 604 688-0173
JParkinsono@protoxtherapeutics.com
infoo@protoxtherapeutics.com
www.protoxtherapeutics.com

March 23, 2009 - Protox Therapeutics Inc. announced that John Parkinson has been appointed Chief Financial Officer of the Company, effective immediately. Mr. Parkinson will replace David Swetlow, Vice President of Finance and Operations, who is leaving Protox to pursue entrepreneurial opportunities.

"John has proven leadership capabilities, business acumen and a track record of successfully managing change and delivering profitable growth," said Dr. Fahar Merchant, President and Chief Executive Officer of Protox. "His wealth of knowledge and experience in the US and Canadian capital markets, managing sizable partnership relationships, as well as his thorough understanding of business operations, will provide tremendous depth to our management team.
John will play an essential role as we continue to advance our business development strategies and broaden and strengthen our relationships with the financial community. He also will be able to work from the foundation built by David during his time with us, who we wish every success in his new endeavor."

Mr. Parkinson has cross-industry experience in the management of high growth, dynamic global companies. Previously, he was Vice President, Finance at Aspreva Pharmaceuticals, a rapidly growing public company formed in 2003 and recently sold to a diversified European healthcare group for over $1 billion. He was a key factor in Aspreva's TSX and NASDAQ $100 million IPO in 2005, the largest in Canadian healthcare history.

Mr. Parkinson co-chaired the Joint Finance Committee with partner Hoffman-La Roche, which held the responsibility for managing the financial elements of their $1.7 billion annual revenue sharing and collaboration agreement. Previously, he focused on financial, high-tech and public company practices during his 10 years with KPMG. He is a member of the Audit and Finance Committee of VIATeC, (the Vancouver Island Advanced Technology Society) and the Institute of Chartered Accountants of British Columbia.

Mr. Parkinson is a graduate of the University of Saskatchewan where he received a Bachelor of Commerce and Bachelor of Arts in Economics.

Top of page

Thomas Dawson, Chief Operating Officer
Ondine Biopharma Corporation
910 - 1100 Melville Street
Vancouver, BC V6E 4A6
Tel. 604 669-0555
Fax. 604 669-0533
TDawsonmhvgcea@ondinebiopharma.com
infomhvgcea@ondinebiopharma.com
www.ondinebiopharma.com

Ms. Taryn Boivin, Ph.D., Vice President, Pharmaceutical Sciences & Manufacturing
Cardiome Pharma Corp
600 - 6190 Agronomy Road
Vancouver, BC V6T 1Z3
Tel. 604 677-6905
Fax. 604 677-6915
adminy9qmsjm@cardiome.com
www.cardiome.com

Dr. Boivin is Cardiome's Vice President of Pharmaceutical Sciences & Manufacturing. Dr. Boivin has over 18 years of Pharmaceutical Development experience in both multi-national and start-up pharmaceutical operations.

Early in her career, Dr. Boivin was a founding member of the Glaxo Canada (Now GSK) Pharmaceutical Development organization and was instrumental in growing the operation into a world-class R&D facility.
While at GSK, Dr. Boivin's work involved progression of development programmes in a wide range of areas including treatments for oncology related emesis, HIV, malaria, ulcers, and asthma.

Following 11 years with Glaxo, Dr. Boivin assumed the responsibility of Business Manager, Life Sciences at Agilent Technologies Inc. (formerly Hewlett Packard) where she led a sales, service, and marketing operation in Central and Western Canada.
More recently, she was Principal of Level 10 BioSciences Ltd., a privately held consulting company on the West Coast., and just prior to joining Cardiome, was Vice President, Pharmaceutical Development at Oncogenex Technologies in Vancouver.

Her experience spans Analytical Development, Pharmaceutical Development, CMC Regulatory Affairs, Quality Assurance, Manufacturing and Business Development.

Dr. Boivin holds a Ph.D. in Chemistry from the University of Alberta and a BSc. from Simon Fraser University.

Steven Whitaker, M.D., J.D., Vice President, Clinical Development and Chief Medical Officer
Allon Therapeutics Inc.
506 - 1168 Hamilton Street
Vancouver, BC V6B 2S2
Tel. 604 736-0634
Fax. 604 736-1616
SWhitakerhj@allontherapeutics.com
infohj@allontherapeutics.com
www.allontherapeutics.com

May 21, 2008 - Allon Therapeutics Inc. announced the appointment of J. Steven Whitaker, M.D., J.D. as Vice President, Clinical Development and Chief Medical Officer of the Company.

Gordon McCauley, President and CEO of Allon, said Whitaker will manage the clinical development and medical affairs related to Allon's expanding program of clinical trials, including interactions with prospective pharmaceutical company partners, regulatory authorities, trial investigators, physicians and patients.

"Steve has enjoyed significant success as a leader in clinical development and regulatory strategy related to products at all stages - from early-stage preclinical development through to international regulatory approval and commercialization," said McCauley.

"In addition, Steve's experience managing a joint venture between a biotech company and a major pharmaceutical company will be invaluable to Allon as we work toward completing a development and commercialization partnership with a major pharmaceutical company in 2008."

Whitaker was Division Vice-President, Clinical Research at ICOS Corporation in Seattle until it was acquired by Eli Lilly and Company (NYSE:LLY - News) in 2007.

Previously, he held a number of roles of increasing responsibility in clinical research and medical affairs after joining ICOS in 1994. Whitaker's achievements include filing with the United States Food and Drug Administration an Investigational New Drug application for approval to start clinical trials and a New Drug Application for marketing approval for the same product.

Whitaker received an M.D. (with highest distinction) from the Indiana University School of Medicine, a J.D. (with highest distinction) from the University Of Washington School Of Law, and a Bachelor of Science in physics and mathematics from Butler University.

Whitaker said being Chief Medical Officer of Allon gives him the opportunity to contribute to a clinical organization dedicated to disease-modifying therapies for neurodegenerative diseases, such as Alzheimer's.

"Allon is a particularly exciting company because it has a promising compound that has demonstrated human efficacy in its Alzheimer's program, a strong team dedicated to helping people, and a can-do culture focused on building a multi-product sustainable company," said Whitaker.

McCauley said Whitaker will work closely with Karole Sutherland, Vice President, Clinical Operations, and Bruce Morimoto, Ph.D., Vice President, Drug Development, who have been instrumental in Allon's successful clinical trial programs to date.

Luke Cyca, Systems Architecture Lead
Zymeworks Inc.
540 - 1385 West 8th Avenue
Vancouver BC V6H 3V9
Tel. 604 678-1388
Fax. 604 737-7077
infolc6zl4@zymeworks.com
www.zymeworks.com

Mr. Cyca is Zymeworks' senior systems architect, overseeing development and operations of the high performance computational infrastructure as well as the integration of our proprietary software platform. Mr. Cyca and his team bring significant experience in the design and management of information technology and software systems. Prior to joining Zymeworks in 2004, Mr. Cyca was founder of NuTok Interactive, a consulting firm focussed on developing new media technologies. Mr. Cyca holds a Bachelors degree in Computing Science from Simon Fraser University.

Andreas Rose, Vice President, Engineering
Ondine Biopharma Corporation
910 - 1100 Melville Street
Vancouver, BC V6E 4A6
Tel. 604 669-0555
Fax. 604 669-0533
ARoseo6j@ondinebiopharma.com
infoo6j@ondinebiopharma.com
www.ondinebiopharma.com

Andreas holds a "Diplom-Ingenieur" degree from University of Applied Sciences in Giessen, Germany. He has gained his considerable expertise as Head of R&D, VP Engineering, and Consultant in Europe, the US and Japan for several market leaders in the field of fiber optics, laser display, and laser technology.

Mr. Rose is well known as an expert in the scientific and industrial field of fiber optics and lasers. He is Short Course Instructor for "Packaging of Optoelectronic Components" at the reputable conference in this field, the "Conference on Lasers and Electro Optics (CLEO).

Top of page

David Saperstein, M.D., Consultant and Interim Chief Medical Officer
QLT Inc.
887 Great Northern Way
Vancouver, BC V5T 4T5
Tel. 604 707-7000
Fax. 604 707-7001
irqsrzg4627@qltinc.com
www.qltinc.com

Saperstein joined QLT Inc. in May 1, 2007, and is a retinal specialist practicing at Vitreoretinal Associates and an active medical staff at Swedish Hospital in Seattle, Washington. Dr. Saperstein specializes in the medical and surgical treatment of retinal diseases and has a special interest in the treatment of age-related macular degeneration (AMD), diabetic retinopathy, surgical diseases of the retina and the management of ocular trauma.

Dr. Saperstein actively participates in clinical trials for the treatment of AMD; he has had continuous and ongoing research funding, has authored several peer reviewed articles, published abstracts and six book chapters, and also received a number of honors and awards.

Dr. Saperstein has also held a number of Faculty positions including Assistant Professor, Department of Ophthalmology, Emory University and Associate Professor, Department Ophthalmology, University of Washington. Dr. Saperstein attended medical school at Pennsylvania State University in Hershey, Pennsylvania after completing his B.S. Electrical Engineering with honors at George Washington University.

Ms. Karimah Es Sabar, President
LifeSciences British Columbia / LifeSciences BC
900 - 1188 West Georgia Street
Vancouver, BC V6E 4A2
Tel: 604 602-5225 - direct
Tel. 604 669-9909 - general
Fax: 604 602-9912
kessabar8@lifesciencesbc.ca
www.bcbiotech.ca

Karimah Es Sabar has had a dynamic career in the healthcare industry globally since 1982, having worked on five continents with business associations in over 60 countries. Ms. Es Sabar has held senior management positions with international multinational companies, most notably as Director International Division, and later Director Marketing & Business Development at Connaught Laboratories Limited [now Aventis Pasteur] based in Toronto.

Amongst her achievements, the company received the Gold Canada Award for Business Excellence in 1992 for the International Division's marketing success in Europe; and she very successfully project managed the company's first biotherapeutic from development to launch worldwide.

More recently Ms. Es Sabar was Vice President and Chief Operating Officer for a North Vancouver medical devices company. She was also the founder and Managing Director of SAL Healthcare Limited, a leading healthcare organization in Kenya specializing in pharmaceutical marketing, distribution and healthcare consulting services. The company set new standards in the marketing and distribution of healthcare products in the region.

She took on the role of Executive Director of BC Biotech in April of 2005, and since that time, has led the organization to its greatest levels of success to date. As one of the primary spokespeople for the biotechnology industry in British Columbia, Ms. Es Sabar regularly represents the industry in key public policy discussions, and parlays her global business development expertise into strong international marketing efforts on behalf of the industry.

Ms.Es Sabar holds BSc. Joint Honours degree in Biochemistry/Chemistry from the University of Salford, England, and a MSc. degree in Neurochemistry from the Institute of Psychiatry, University of London, England.

Dr. Allen Eaves, President
Stemsoft Software Inc.
401 - 570 West 7th Avenue
Vancouver, BC V5Z 1B3
Tel. 604 668-0854
Tel. 800 667-0322
Fax. 604 877-0704
Allenpc9b3v1t@stemcell.com
infowebpc9b3v1t@stemcell.com
stemsoftpc9b3v1t@stemsoft.com
www.stemsoft.com
www.stemcell.com

Dr. Allen Eaves is also President of StemCell Technologies Inc.

Christopher Gallen, M.D., Ph.D., President and Chief Executive Officer
Neuromed Pharmaceuticals Ltd.
301 - 2389 Health Sciences Mall
Vancouver, BC V6T 1Z4
Tel. 604 909-2530
Fax. 604 909-2538
cgallenk19h@neuromed.com
infok19h@neuromedtech.com
www.neuromedtech.com

Dr. Gallen joined Neuromed in July 2004 as President & CEO and has led the company to two of its private equity financings, a transformative licensing deal with Merck & Co. and an acquisition of the U.S. marketing rights of a Phase 3 chronic pain product from ALZA Corporation.

Dr. Gallen has extensive experience in clinical and corporate development and has been instrumental in the commercialization of several drugs. Most recently, Dr. Gallen was Vice President and Chief of Operations, Clinical Research and Development at Wyeth Research in charge of global clinical operations including clinical trial management, data management, biostatistics, clinical communications, procedural compliance and training and was a key driver in the re-engineering of Wyeth Clinical Research and Development.

Prior to Wyeth, Dr. Gallen was VP of Clinical Research at Pharmacia and was responsible for overseeing global CNS development and clinical operations for all specialties and clinical research in the Western Hemisphere. Previous positions include President of the CRO division at Premier Research Worldwide, where he was a key contributor to a successful IPO, and Senior Director of Medical and Scientific Services at Quintiles International Clinical Research Corporation.

Dr. Gallen received his M.D. and Ph.D. (Biochemistry) from the Emory University School of Medicine in Atlanta, Georgia and completed residencies in Psychiatry at Stanford and in Neurology at UCSD.

Michael Patrick, B.Sc., Senior Manager of Information Technology
Kinexus Bioinformatics Corporation
402 - 6190 Agronomy Road
Vancouver, BC V6T 1Z3
Tel. 604 822-9963
Fax. 604 822-9964
infoqg592@kinexus.ca
www.kinexus.ca

Michael Patrick joined Kinexus in May 2005 and leads the company's information technology initiatives. He is responsible for developing an innovative and focused IT architecture and strategy that supports and extends Kinexus overall business goals and direction.

Mr. Patrick has over thirteen years experience with information technology. This includes time as head of IT for a global clinical research organization undergoing explosive growth as well as consulting engagements for the College of Physicians and Surgeons and the Michael Smith Foundation.

He has a strong background in project management, database development and system maintenance. Prior to this he spent several years teaching networking and database design for a division of IBM. At present he is completing his MBA through the Management of Technology program at Simon Fraser University.

Top of page

Dr. Samuel Denmeade, Chief Scientific Officer
Protox Therapeutics Inc.
1210 - 885 West Georgia Street
Vancouver, BC V6C 3E8
Tel. 604 688-0199
Fax. 604 688-0173
SDenmeadeap@protoxtherapeutics.com
infoap@protoxtherapeutics.com
www.protoxtherapeutics.com

October 23, 2007 - Protox Therapeutics announced that it has appointed Dr. Samuel Denmeade to the position of Chief Scientific Officer.

Susan Ogilvie, Director, Communications & Editor-in-Chief, The Tablet
British Columbia Pharmacy Association
1530 - 1200 West 73rd Avenue
Vancouver, BC V6P 6G5
Tel. 604 261-2092
Fax. 604 261-2097
susan.ogilvieto3d2l2t@bcpharmacy.ca
infoto3d2l2t@bcpharmacy.ca
www.bcpharmacy.ca

Dr. John Husnik, Senior Research Scientist
First Venture Technologies Corp.
1500 - 885 West Georgia Street
Vancouver, BC V6C 3E8
Tel. 604 648-2200
Fax. 604 648-2201
infor1265i1zj@firstventuretechnologies.com
www.firstventuretechnologies.com

July 12, 2007 - First Venture Technologies Corp. is pleased to announce the appointments of Dr. John Husnik in the role of Senior Research Scientist, and of Mr. Bryan Avila to the position of Technical Projects Leader.

John is a leading-edge microbiologist and an expert in the area of wine yeast genetics. He was previously with the University of British Columbia's Wine Research Centre where he was the technical lead on the development of the urea-degrading yeast technology.

John's recent publications in peer-reviewed journals demonstrate his unique expertise in the successful development of functionally-enhanced yeast strains. His major contributions to the urea-degrading yeast technology have been presented at national and international conferences on numerous occasions.

John's prior work and training experience includes having direct and extensive collaborations with a leading global yeast producer and several research centres.

Vancouver, BC Biotechnology and Pharmaceutical Companies directory and business contacts list

Make your "cold calls" warmer